Seralutinib advances toward NDA filing as Gossamer Bio cites strong data
Gossamer Bio says positive FDA interactions and robust clinical data support an imminent NDA filing for seralutinib. The company highlights efficacy in key subgroups, a favorable safety profile, and a CTD-associated PAH positioning focus.